CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

Shares of Biomea Fusion drew heightened attention from retail investors on Tuesday after the company disclosed a public ...

I-Mab (NASDAQ: IMAB) (the "Company”), a U.S.-based, global biotech company, focused on the development of precision ...

AI could help radiologists identify a significant number of interval breast cancer cases earlier in the screening process, according to results of a retrospective study.A commercial AI program ...

Bristol Myers Squibb has declared a quarterly dividend of $0.62 per share, maintaining its impressive 55-year streak of ...